Human Vaccine Adjuvant
Your One-Stop Partner.
QS-21 (GMP Standards), Matrix-M™, QS-7, QS-17, QS-18 — the most clinically validated adjuvants in the commercial vaccine market.
The Gold Standard Adjuvant
QS-21 is one of the most successful adjuvants in the current commercial human vaccine market. As a naturally derived saponin mixture, it has been widely applied in the research, development and production of various vaccines.
By efficiently enhancing immune responses and inducing long-lasting immune memory, it provides crucial support for the clinical efficacy of vaccines.
The raw material is derived from Quillaja Saponaria Molina (soapbark tree), an evergreen tree that grows abundantly in Chile. Desert King maintains full supply chain control from forest-sourced raw materials to final product.
Production Process
Extraction & Isolation
High-purity chromatography isolation of QS-21 fraction from Quillaja bark extract.
GMP Manufacturing
Desert King facilities in Chile, Mexico, and Italy. GMP-certified Italian facility operational.
Supply Chain Control
Full vertical control from forest raw materials to final GMP-grade product.
Validated in 3 Commercial Vaccines
| Vaccine Type | Representative Vaccine | Adjuvant System |
|---|---|---|
| Shingles Vaccine | Shingrix | QS-21 |
| RSV Vaccine | Arexvy | QS-21 |
| Malaria Vaccine | Mosquirix (RTS,S) | ASO1, ASO2, ALFQ, Matrix-M |
| COVID-19 Vaccine | COVID-19 Vaccine | Matrix-M |
Over 20 Phase I-II clinical trials currently underway covering HIV, cancer, herpes, Alzheimer's, and more.
Why QS-21?
Potent Immune Enhancement
Simultaneously promotes antibody production and cellular immunity. Particularly effective for vaccines targeting intracellular pathogens and cancer.
Significant Synergistic Effect
Combines with other adjuvants to form composite systems (AS01, Matrix-M), amplifying immune response effect.
High Formulation Versatility
Applicable to multiple formulation types, supporting R&D and production of vaccines for different diseases.
Durable Immune Protection
Induces long-term immune memory, providing sustained protection for many years after vaccination.
Sufficient Clinical Validation
In Shingrix shingles vaccine, effectiveness reaches over 95%, fully demonstrating its clinical value.
Sustainable & Scalable
Hundreds of grams of valid GMP-grade QS-21
Current GMP Inventory
5 kg (expandable to 10 kg)
Annual Production
20,000–40,000 doses
Human Doses per gram
200–400 million human doses
Projected Capacity
Raw materials harvested via selective bark pruning — trees regenerate in 5–8 years. FSC-certified supply chain. Hundreds of hectares of Quillaja saponaria plantations secured.
Interested in QS-21 or Vaccine Adjuvants?
Contact VuRoyal to discuss your vaccine adjuvant sourcing needs with our expert team.
Contact Us